An evaluation of glasdegib for the treatment of acute myelogenous leukemia. (23rd March 2020)

• Record Type: Journal Article
• Authors: Thomas, Xavier; Heiblig, Maël
• Is Part Of: Expert opinion on pharmacotherapy. Volume 21:Number 5(2020)
• Page Start: 523
• Page End: 530
• Publication Date: 2020-03-23
• Subjects: Acute myeloid leukemia -- elderly -- treatment -- new agents -- SMO inhibitor -- Hedgehog signaling; Chemotherapy -- Periodicals; 615.5805
• DOI: 10.1080/14656566.2020.1713094
• Languages: English
• ISSNs: 1465-6566

Abstract

ABSTRACT: Introduction: Despite recent advances in the treatment of adult acute myelogenous leukemia (AML), the overall outcome remains dismal especially in high-risk AML patients, including the elderly and the relapsed/refractory populations. In this setting, various clinical trials have recently explored novel therapeutic agents either used alone or in combination with intensive chemotherapy or low-intensity treatments. Areas covered: The current paper reviews the clinical development of glasdegib, a selective inhibitor of the Hedgehog signaling pathway through binding to its target SMO, for the treatment of AML. Expert opinion: Glasdegib confirmed its efficacy and showed an acceptable tolerability, especially when used in combination either with '3 + 7ʹ chemotherapy or with low-intensity therapies. In 2018, glasdegib was approved by the Food and Drug Administration (FDA) in combination with low-dose cytarabine for the treatment of newly diagnosed AML in patients older than 75 years or presenting with severe comorbidities.